2.2. Study Protocol
cognitive and executive function
Testing took place at various community centers across the country. Participants met with the study team on three separate occasions. At the first visit (PRE), participants received an explanation about the study, provided their informed consent, and were randomized into either the BA (15 men and 35 women; 68.4 ± 6.1 y; 168.5 ± 10.4 cm and 77.9 ± 16.2 kg) or the placebo group (PL; 14 men and 36 women; 70.8 ± 9.3 y; 165.0 ± 9.1 cm and 71.4 ± 13.8 kg). Before taking their first supplement, participants completed several tests consisting of written questionnaires to assess cognitive function and mood and a computer-based exam to measure cognitive and executive function. In addition, a series of physical function tests were also performed. At the end of the testing session, participants were provided with a bottle containing the supplement or placebo. They were given instructions on how and when to take the supplement and that they should bring the bottle back to the community center at the next testing session. Testing was also conducted at weeks 5 (MID) and 10 (POST). At MID, participants provided their supplement bottles and received new bottles. To determine participant compliance, the number of capsules remaining in the bottle were counted and recorded. Participants completed the same testing protocol in the same order as completed during PRE. The same procedure was completed at POST, except that participants were not given a new bottle.